


Amendments to the Claims

The following listing of claims will replace all prior versions and listings of claims in the application.

1. (Currently amended) A compound of formula I,




(I)

or a pharmaceutically acceptable salt thereof.

2. (Currently amended) The compound according to claim 1, wherein the compound is [being] 8-[(2,6-dimethylbenzyl)amino]-N-[(2S)-2-hydroxypropyl]-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide mesylate salt.


3. (Currently amended) A process for the preparation of a compound according to claims 1 or 2, comprising the steps of:

- a) treating a compound of Formula II,




wherein R¹ represents a C₁-C₆-alkoxy group or -NH₂,

~~[in the presence of]~~ with an aqueous acid or base ~~[,]~~ under standard conditions, to form a compound of Formula III; and



b) reacting the compound of Formula III with a compound of Formula IV,



in the presence of a coupling reagent in an inert solvent under standard conditions, to give a compound of Formula I, and optionally converting the compound of Formula I to a pharmaceutically acceptable salt.


4. (Canceled)

5. (Currently amended) A pharmaceutical formulation comprising the ~~[containing a]~~ compound according to claim 1 or 2 as active ingredient in combination with [a] one or more pharmaceutically acceptable diluents or carriers.

6. (Canceled)

7. (Currently amended) A method ~~[of treatment and/or inhibiting]~~ for the treatment or inhibition of a gastric acid related disease[s], gastrointestinal inflammatory disease[s], heartburn, symptomatic GERD, erosive esophagitis, peptic ulcer disease, regurgitation, acid reflux ~~[diseases]~~ disease, or nausea in ~~[human or non-human mammal which comprises]~~ a patient, the method comprising administering an effective amount of a compound according to claim 1 or 2 ~~[, to a human or non-human mammal]~~ to the patient in need thereof.

8. (Currently amended) A compound of Formula III,



(III)